Parameters | Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
HR1 | 95% CI2 | p | HR | 95% CI | p | |
Age | 0.99 | 0.98 - 1.01 | 0.745 | Â | Â | Â |
gender (male vs. female) | 1.43 | 0.96 - 2.14 | 0.082 | Â | Â | Â |
Intrahepatic tumor expansion (multifocal vs. oligonodular) | 1.74 | 1.23 - 2.47 | 0.002 | 1.63 | 1.11 - 2.42 | 0.014 |
Tumor size (cm) | 1.00 | 0.97 - 1.04 | 0.889 | Â | Â | Â |
ECOG | Â | Â | 0.127 | Â | Â | Â |
 0 | 1 |  |  |  |  |  |
 1 | 1.04 | 0.69-1.58 |  |  |  |  |
 2 | 1.50 | 1.01-2.22 |  |  |  |  |
Treatment | Â | Â | <0.001 | Â | Â | 0.007 |
 No therapy | 1 |  |  | 1 |  |  |
 Sorafenib | 0.62 | 0.43 – 0.91 | 0.013 | 0.86 | 0.56 – 2.26 | 0.475 |
 TACE | 0.45 | 0.30 – 0.66 | <0.001 | 0.54 | 0.35 – 0.84 | 0.006 |
 TACE and sorafenib | 0.41 | 0.25 – 0.68 | <0.001 | 0.48 | 0.28 – 0.81 | 0.006 |
ALBI | Â | Â | <0.001 | Â | Â | <0.001 |
 ALBI 1 | 1 |  |  | 1 |  |  |
 ALBI 2 | 1.63 | 1.15 - 2.31 | 0.006 | 1.56 | 1.10 - 2.30 | 0.026 |
 ALBI 3 | 3.33 | 2.15 - 5.15 | <0.001 | 3.42 | 2.09 - 5.61 | <0.001 |
viral vs. non-viral etiology | 0.89 | 0.65 - 1.20 | 0.432 | Â | Â | Â |
Segmental portal vein thrombosis | 1.12 | 0.97 - 1.29 | 0.128 | Â | Â | Â |
AFPÂ >Â 400Â ng/ml | 1.51 | 1.13 - 2.01 | 0.005 | 1.50 | 1.10 - 1.92 | 0.010 |
BCLC (C vs. D) | 5.15 | 3.31 - 8.02 | <0.001 | 2.45 | 1.42 – 4.29 | 0.001 |
multiple metastases | 0.96 | 0.69 - 1.33 | 0.797 | Â | Â | Â |